R&D Programs

aptaTargets starts Phase 1b/2a clinical trial with ApTOLL in stroke patients
Oct, 2020
aptaTargets starts Phase 1b/2a clinical trial with ApTOLL in stroke patients

view press releaseDownload
aptaTargets closes a second round of €5 million
Oct, 2020
aptaTargets closes a second round of €5 million

Inveready and the CDTI through the INNVIERTE program will invest €2.3 million of capital. This amount will be complemented by €2.7 million through other instruments and public funds that have already been obtained. With these funds, aptaTargets plans to advance up to a clinical proof of concept in acute ischemic stroke patients. 


view press releaseDownload
ApTOLL efficacy in myocardial infarction
Aug, 2020
ApTOLL efficacy in myocardial infarction

Ramirez-Carracedo et al. Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction. 

Biomolecules. Aug 9;10(8):1167. doi:10.3390/biom10081167.

Authorization to start the APRIL trial
Jul, 2020
Authorization to start the APRIL trial
The Spanish regulatory agency has approved the APRIL clinical trial, a Phase 1b/2a study to assess the safety and efficacy of ApTOLL in acute ischemic stroke patients.
RETOS funding for the ApTOLL stroke program
Jul, 2020
RETOS funding for the ApTOLL stroke program
Consortium formed by aptaTargets and the Vall d’Hebron Hospital (VHIR) have been awarded by the Retos-Colaboracion program. The project and the €1,4 million will be focused on the clinical development of ApTOLL.
Torres Quevedo grant
Jun, 2020
Torres Quevedo grant
aptaTargets gets a grant from the Torres Quevedo Program (Ministerio Economia). 
aptaTargets announces completion of enrollment in the Phase I study of ApTOLL in healthy volunteers
Mar, 2020
aptaTargets announces completion of enrollment in the Phase I study of ApTOLL in healthy volunteers
aptaTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.
EIT Health
Jun, 2019
EIT Health
aptaTargets has been awarded with the Bridgehead Program.
First Patient in the ApTOLL-FIH-01 trial: <span class="light">a Phase I trial in healthy volunteers</span>
Jun, 2019
First Patient in the ApTOLL-FIH-01 trial: a Phase I trial in healthy volunteers
aptaTargets has started the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.
aptaTargets: finalist award <span class="light">at the EIT Health annual meeting 2018</span>
Dec, 2018
aptaTargets: finalist award at the EIT Health annual meeting 2018
aptaTargets attended the EIT health annual meeting held at the IESE Business School in Barcelona and was awarded with the finalist award of the Spanish Health Catapult program. aptaTargets is part of the EIT Health community and during 2018 has also been awarded with the EIT Health Headstart program.
aptaTargets gets new funding from the RETOS-program <span class="light"> for exploring inflammatory pathologies</span>
Dec, 2018
aptaTargets gets new funding from the RETOS-program for exploring inflammatory pathologies
A Consortium led by aptaTargets has been awarded with public funding from the RETOS program for exploring new indications for ApTOLL, a DNA aptamer targeting TLR4 with an anti-inflammatory effect. The Consortium RETOS-SafeTOLL (RTC-2017-6283-1) is also composed by the Neurovascular Research Unit (Complutense University, Madrid) and the Institute of Biomedical Research (UAM-CSIC, Madrid) and has a total budget of 503,800 EU.
RETOS funding for the ApTOLL stroke program
Dec, 2018
RETOS funding for the ApTOLL stroke program
aptaTargets is the leader of the NeuroToll project, aiming to the clinical development of ApTOLL, an innovative neuroprotective drug for the acute treatment of stroke. The project focuses in stroke program, advancing from late preclinical phase and up to clinical trials Phase II in stroke patients. The project has obtained funding from the Ministry of Science, Innovation and Universities through the RETOS-COLABORACION program, which includes FEDER funding (RTC-2017-6651-1). The consortium is formed by aptaTargets along with several hospitals of reference in the stroke field, such as Germans Trias i Pujol (HGTiP, Barcelona), La Princesa (HULP, Madrid), Virgen del Rocio and Macarena (FISEVI, Sevilla). The project has an aggregated budget of around 3.1 M EU.
aptaTargets: awarded by Doctorado Industrial Program
Nov, 2018
aptaTargets: awarded by Doctorado Industrial Program
(Comunidad de Madrid). The project involves a doctoral program aiming the study of further application of ApTOLL in Multiple Sclerosis.
EIT Health
Sep, 2018
EIT Health
aptaTargets has been awarded with the Headstart Program.
aptaTargets gets funds from NEOTEC Program
Mar, 2018
aptaTargets gets funds from NEOTEC Program
The Spanish Centre for the Development of Industrial Technology (CDTI) has granted aptaTargets with funds from the Neotec Program. aptaTargets aims to advance in the pre-clinical and clinical development of ApToll (a molecule based on aptamer technology and targeting inflammation) in acute ischemic stroke and other indications (myocardial infarction and Multiple Sclerosis).
aptaTargets closes €2.7- million round of funding for new stroke treatment
Jan, 2016
aptaTargets closes €2.7- million round of funding for new stroke treatment
'la Caixa', throught their venture capital arm Caixa Capital Risc, and Inveready have invested €2.7 million in aptaTargets, which will allow this biopharmaceutical company to complete the preclinical phase and move into phase I and II clinical trials on its first drug candidate (ApTOLL) to treat acute ischemic stroke. Press release
ApTOLL gets funds from Retos-2015 Program
Dec, 2015
ApTOLL gets funds from Retos-2015 Program

The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company aptaTargets and are also participating Aptus Biotech, the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.

Oct, 2020
aptaTargets closes a second round of €5 million

Inveready and the CDTI through the INNVIERTE program will invest €2.3 million of capital. This amount will be complemented by €2.7 million through other instruments and public funds that have already been obtained. With these funds, aptaTargets plans to advance up to a clinical proof of concept in acute ischemic stroke patients. 


view press releaseDownload
Read More
Aug, 2020
ApTOLL efficacy in myocardial infarction

Ramirez-Carracedo et al. Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction. 

Biomolecules. Aug 9;10(8):1167. doi:10.3390/biom10081167.

Read More
Jul, 2020
RETOS funding for the ApTOLL stroke program
Consortium formed by aptaTargets and the Vall d’Hebron Hospital (VHIR) have been awarded by the Retos-Colaboracion program. The project and the €1,4 million will be focused on the clinical development of ApTOLL.
Read More
Mar, 2020
aptaTargets announces completion of enrollment in the Phase I study of ApTOLL in healthy volunteers
aptaTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.
Read More
Jun, 2019
First Patient in the ApTOLL-FIH-01 trial: a Phase I trial in healthy volunteers
aptaTargets has started the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.
Read More
Dec, 2018
aptaTargets: finalist award at the EIT Health annual meeting 2018
aptaTargets attended the EIT health annual meeting held at the IESE Business School in Barcelona and was awarded with the finalist award of the Spanish Health Catapult program. aptaTargets is part of the EIT Health community and during 2018 has also been awarded with the EIT Health Headstart program.
Read More
Dec, 2018
aptaTargets gets new funding from the RETOS-program for exploring inflammatory pathologies
A Consortium led by aptaTargets has been awarded with public funding from the RETOS program for exploring new indications for ApTOLL, a DNA aptamer targeting TLR4 with an anti-inflammatory effect. The Consortium RETOS-SafeTOLL (RTC-2017-6283-1) is also composed by the Neurovascular Research Unit (Complutense University, Madrid) and the Institute of Biomedical Research (UAM-CSIC, Madrid) and has a total budget of 503,800 EU.
Read More
Dec, 2018
RETOS funding for the ApTOLL stroke program
aptaTargets is the leader of the NeuroToll project, aiming to the clinical development of ApTOLL, an innovative neuroprotective drug for the acute treatment of stroke. The project focuses in stroke program, advancing from late preclinical phase and up to clinical trials Phase II in stroke patients. The project has obtained funding from the Ministry of Science, Innovation and Universities through the RETOS-COLABORACION program, which includes FEDER funding (RTC-2017-6651-1). The consortium is formed by aptaTargets along with several hospitals of reference in the stroke field, such as Germans Trias i Pujol (HGTiP, Barcelona), La Princesa (HULP, Madrid), Virgen del Rocio and Macarena (FISEVI, Sevilla). The project has an aggregated budget of around 3.1 M EU.
Read More
Mar, 2018
aptaTargets gets funds from NEOTEC Program
The Spanish Centre for the Development of Industrial Technology (CDTI) has granted aptaTargets with funds from the Neotec Program. aptaTargets aims to advance in the pre-clinical and clinical development of ApToll (a molecule based on aptamer technology and targeting inflammation) in acute ischemic stroke and other indications (myocardial infarction and Multiple Sclerosis).
Read More
Jan, 2016
aptaTargets closes €2.7- million round of funding for new stroke treatment
'la Caixa', throught their venture capital arm Caixa Capital Risc, and Inveready have invested €2.7 million in aptaTargets, which will allow this biopharmaceutical company to complete the preclinical phase and move into phase I and II clinical trials on its first drug candidate (ApTOLL) to treat acute ischemic stroke. Press release
Read More
Dec, 2015
ApTOLL gets funds from Retos-2015 Program

The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company aptaTargets and are also participating Aptus Biotech, the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.

Read More

Future Conference Attendance

Attended Conferences

0
Feb, 2020Los Angeles
International Stroke Conference 2020
Marc Ribó (CMO) and Macarena Hernández (CSO) attended the 2020 ISC at Los Angeles, California. Marc moderated the session “Expanding Indications for Thrombectomy” and presented an artificial intelligence algorithm that helps to evaluate acute stroke patients.
Read More
0
Nov, 2019Amsterdam
BioEurope 2019

aptaTargets participated in the round table about therapeutic aptamers, presenting the nonclinical program.

Read More
0
Nov, 2019Amsterdam
Tides Europe

aptaTargets participated in the round table about therapeutic aptamers, presenting the nonclinical program, regulatory management and preliminary results in First-in-Human trial.

Read More
0
May, 2019Milan
ESOC

(European Stroke Organization Conference)
aptaTargets presented the First-in-Human clinical study design.

Read More